688076 诺泰生物
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)3.0017.9866.9388.31713.730
总资产报酬率 ROA (%)1.8265.3695.5546.5529.351
投入资产回报率 ROIC (%)1.9815.8796.0097.14210.102

边际利润分析
销售毛利率 (%)67.26460.97057.57355.75658.164
营业利润率 (%)22.71418.35119.17019.92825.370
息税前利润/营业总收入 (%)23.52217.87218.88519.92529.310
净利润/营业总收入 (%)18.14616.00818.85016.89921.174

收益指标分析
经营活动净收益/利润总额(%)108.241119.14384.003103.92882.638
价值变动净收益/利润总额(%)0.2161.82614.6152.5594.386
营业外收支净额/利润总额(%)-0.459-9.553-1.375-2.0541.873

偿债能力分析
流动比率 (X)1.4561.5361.9094.0091.277
速动比率 (X)1.0851.1481.3223.0980.793
资产负债率 (%)39.01138.28223.68514.95830.779
带息债务/全部投入资本 (%)32.19329.91915.1736.859--
股东权益/带息债务 (%)202.103224.103545.8821,326.533367.521
股东权益/负债合计 (%)155.080159.820319.750569.371224.269
利息保障倍数 (X)25.79015.938-752.24250.1028.482

营运能力分析
应收账款周转天数 (天)79.67094.334106.36068.9950.000
存货周转天数 (天)298.124312.642374.107275.3700.000